

References

(A)

.Abu- Shakra M, Urowitz MB, Gladman DD,et al (1995):-

Systemic lupus erythematosus. Result from a single center; Causes of death J Rheumatol ;22(7): 1259 – 64.

.Anisur Rahman and David A. Isenberg (2008):-

"Review Article: Systemic Lupus Erythematosus". N Engl J Med 358 (9): 929–939.

. Appel GB, Blum CB, Chien S, et al., (1985):-

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312(24):1544–1548.

.Appel GB, Pirani CI, DAgati V (1994):-

Renal vascular complications of systemic lupus erythematosus. Am J Soc nephrol;4:1499-1515.

.Appel GB, Radhakrishnan J, Avram MM et al.,(2003):-

Analysis of metabolic parameters as predictors of risk in RENAAL study. Diabetes Care; 26:1402-7.

. Arbuckle MR, McClain MT, Rubertone MV et al., (2003):- Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. ;349(16):1526-33.

.Arodin SP, Sandborg C and Schanberg LE, (2007):-

Management of dyslipidemia in children and adolescents with systemic lupus erythematosus. *Lupus*; 16:618-626.

. Aronson D, Sella R, Sheikh-Ahmad M, et al., (2004):-

The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. *J Am Coll Cardiol* 44: 2003–2007.

. Asanuma Y, Churg CP, Oeser A, et al., (2006):-

Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: Relationship to cardiovascular risk factors. *J Rheumatol*; 33(3):539-545.

. Attman PO, Alaupovic P. (1991):-

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia—relation to renal function and dialysis. *Nephron* 57(4):401–410.

. Austin, H.A. III; Muenz, L.R.; Joyce, K.M. et al. (1984):-

Diffuse proliferative lupus nephritis: Identification of specific pathologic features from renal biopsy in systemic lupus erythematosus: Stepwise multiing renal outcome. *Kidney Int* 25:689–695.

(B)

.Bairaktari E, Elisaf M, Katsaraki A, et al, (1999):-

"Homogeneous HDL-cholesterol assay versus ultracentrifugation/dextran sulfate-Mg²⁺ precipitation and dextran sulfate-Mg²⁺ precipitation in healthy population and in hemodialysis patients". *Clinical Biochemistry* 32 (5): 339.

. Bass KM, Newschaffer CJ, Klag MJ, Bush TL.,(1993):-

Plasma lipoprotein levels as predictors of cardiovascular death in

women. Arch Intern Med 153:2209–2216.

. Beutler B, Mahoney J, Le Trang N, et al., (1985):-

Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 161:984–995.

. Bigler C, Lopez-Trascasa M, Potlukova E, Moll S, Danner D, Schaller M, et al., (2008):-

Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. ;51(4):624-9.

.Biochemistry 2nd Ed. 1995 Garrett & Grisham

.Bombardier C, Gladman DD, Urowitz MB, Caron D, and Chang CH, (1992):-

The committee on prognosis studies in SLE. Deviation of the SLEDAI:A disease activity for lupus patients. Arthritis Rheum 35:630-640.

.Borba EF and Bonfa E.,(1997):-

Dyslipoproteinemia in systemic lupus erythematosus: Influence of disease activity and anticardiolipin antibodies. Lupus ;6: 533-539.

.Borba EF and Bonfa E.,(2001):-

Longterm beneficial effects of chloroquin diphosphate on lipoprotein profile in lupus patients with an without steroid therapy. J Rheumatol; 28(4): 780-785.

.Borba EF and Bonfa E, Vivagre CG, et al.,(2000):-

Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum ; 43: 1033-1040.

.Borba EF, Carvalho JF and Bonfa E,(2006):-

Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. *Clinical Dev Immunol* ;13(2-4): 203-208.

.Brewer, H. Bryan (2005):-

"Raising HDL-Cholesterol and Reducing Cardiovascular Risk: An Expert Interview With H. Bryan Brewer, Jr, MD".

.Brown WV. 1994:-

Lipoprotein disorders in diabetes mellitus. *Med Clin North Am* 78:143–161.

.Brown MS and Goldstein JL (1986):-

A receptor-mediated pathway for cholesterol homeostasis. *Science* 232:34-47.

.Brown MS, Goldstein JL (1997):-

"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor". *Cell* 89 (3): 331.

.Bruce IN, Urowitz MB, Gladman DD et al.,(1999):-

Natural history of hypercholesterolemia in systemic lupus erythematosus. *J Rheumatol*:26:2137-43.

.Bruce IN, Burns RJ, Gladman DD et al., (2000):-

Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. *J Rheumatol* 27:2372–2377.

.Bruce IN, Urowitz MB, Gladman DD et al., 2003:-

Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. *Arthritis Rheum* 48(11): 3159-3167.

.Brunner HI, Gladman DD, Ibañez D, Urowitz MD and Silverman ED, (2008):-

Difference in disease features between childhood-onset and adult-onset systemic

lupus erythematosus. *Arthritis Rheum.* ;58(2): 556-62.

.Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL (2008):-

"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation". *Diabetes Care* 31 (4): 811–22.

.Bujan S, Ordi- Ros J, Paredes J, Mauri M, Matas L, Cortes J and Vilardell M (2003):

Contribution of the initial features of systemic lupus erythematosus to the clinical evolution and survival of a cohort of Mediterranean patients. *Ann Rheum Dis*; 62 (9):859- 865.

.Burstein D.M., Schwartz M.M and. Korbet S.M (1991) :-

Percutaneous renal biopsy with the use of real-time ultrasound. *Am. J. Nephrol.* pp. 195–200.

(C)

.Carneiro E., Reis C., Pinto P., ET AL., (2006) :-

Systemic lupus erythematosus: imaging of central nervous system involvement by magnetic resonance. *Acta Med Port.*; 19(6):459-65. Epub May 14.

.Carr MC, Ayyobi AF, Murdoch SJ, et al.,(2002):-

Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl estertransfer protein to LDL and HDL heterogeneity in healthywomen. *Arterioscler Thromb Vasc Biol*, 22:667–673.

.Chapman, M. John; Assmann, Gerd; Fruchart, Jean-Charles; Shepherd, James; Sirtori, Cesare; European Consensus Panel on HDL-C (2004):-

"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C". Current medical research and opinion 20 (8): 1253–68.

. Chisolm GM, Steinberg D.,(2000):-

The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med, 28:1815–1826.

"Cholesterol Levels". American Heart Association.(2009).

. Christie, William (2003):-

Lipid analysis: isolation, separation, identification, and structural analysis of lipids. Ayr, Scotland: Oily Press. ISBN 0-9531949-5-7.

. Churg J, Bernstein J and Glassock R.J, (1995):-

Lupus nephritis. En: Classification and Atlas of Glomerular Disease, 2nd ed. New York, Igaku-Shoin, , p51.

.Claudia RL, Cardoso-Flavo V. Signorelli et al ., (2008):-

Prevalance and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol Int;28:323-327.

. Coblyn J.S., and Weinblatt M.E. (1997):-

Rheumatic diseases and the heart. "SystemicLupus Erythematosus", In: Heart disease. " A textbook of cardiovascular medicine. Edited by: Braunwald E., 5th edition; Chap. 56: P. 1776.

.Cockerill GW, Rye KA, Gamble JR et al., (1995):-

High- density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. *Arterioscler Thromb Vasc Biol* ; 15:1987-1994.

. Cohen M.R., and Isenberg D.A. (1996):-

Ultraviolet irradiation in systemic lupus erythematosus: Friend or foe? *Br. J. Rheumatol.*;35: 1002.

. Contreras G, Pardo V, Leclercq B, et al., (2004):-

Sequential therapies for proliferative lupus nephritis. *N Engl J Med.* ; 350 (10): 971-80.

.Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS (2007):-

Prevalence of chronic kidney disease in the United States. *JAMA.*;298(17):2038-47.

.Costenbader KH, Wright E, Liang KH et al., 2004:-

Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. *Arthritis Rheum* 51: 983-988.

.Crook ED, Thallapureddy A, Migdal S, et al.,(2003):-

Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? [review]. *Am J Med Sci*;325:340-8.

. Crow MK, (2008):-

Collaboration, genetic associations, and lupus erythematosus. *N Engl J Med.* ;358(9):956-61.

(D)

. David W, Xamont D and Mai Kirn Lai, (2006):-

Systemic lupus erythematosus. *Rheum Dis Clin North Am.* ; 32(1): 150-160.

. D'Agati VD and Appel GB. (2007) :-

Lupus Nephritis Pathology and Pathogenesis. In: Wallace DJ, Hahn BH. *Dubois' Lupus Erythematosus*. 7th ed . Philadelphia,PA: Lippincott Williams & Wilkins; :1094-111.

. de Carvalho JF, Borba EF, Viana VS, et al(2004):-

Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? *Arthritis Rheum*, 50:3610–3615.

. Delgado-Alves J, Ames PR, Donohue S, et al(2003):-

Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. *Arthritis Rheum*, 46:2686–2694.

. Després, Jean-Pierre, (2009):-

"The Atherogenic Triad of New Metabolic Risk Factors: Importance of Waist and Fasting Triglycerides as Screening Tools". *Visceral Adipose Tissue and Cardiometabolic Risk: Does It Really Matter? Part 2.*

. Diaz-Buxo J.A. and Donadio J.V, (1975) :-

Complications of percutaneous renal biopsy: an analysis of 1,000 consecutive biopsies. *Clin. Nephrol.* **4**, pp. 223–227

. Dinu AR, Merrill JT, Shen C, et al(1998):-

Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. *Lupus*, 7:355–360.

. Dooley MA., Wallace DJ, Hahn BH, et al., (2007) :-

Clinical and laboratory features of lupus nephritis. In: eds. Dubois' *Lupus Erythematosus*. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; :1112-30.

.Drexel, H. (2006):-

"Reducing risk by raising HDL-cholesterol: the evidence". *European Heart Journal Supplements* 8: F23.

. Durrington P (2003):-

"Dyslipidaemia". *Lancet* 362 (9385): 717–31.

(E)

. Edworthy S.M. (2005):-

Clinical manifestations of systemic lupus erythematosus. In: *Kelley's textbook of rheumatology*. Edited by: Harris E.D., Budd R.C., and Sledge C.B. 7th edition. Elsevier, Saunders. Chap. 75; P. 1201.

.Emma Leah(2009):-

"Cholesterol". *Lipidomics Gateway*. doi:10.1038/lipidmaps. 3.

Esdaile JM, Abrahamowicz M, Grodzicky T, et al. (2001):-

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 44:2331–2337.

. Espenshade PJ, Hughes AL (2007):-

"Regulation of sterol synthesis in eukaryotes". *Annu. Rev. Genet.* 41: 401–27.

(F)

.Feingold KR, Grunfeld C(1992):-

Role of cytokines in inducing hyperlipidemia. Diabetes, 41(Suppl 2):97–101.

.Fernand MM, Phillip KT, Paul CL et al., (2000):-

Histological appraisal of lupus nephritis.Hongkong J of nephrology;2(1).1233-1240.

.Font J, Ramos-Casals, Cervera R et al., (2000):-

Cardiovascular risk factors and thhe long-term outcome of lupus nephritis.Q J Med;94:19-26.

.Fredrikson GN, Hedblad B, Nilsson JA, et al. (2004):-

Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 53:1436–1442.

.Fried LF, Orchard TJ, Kasiske BL,(2001):-

Effectof lipid reduction on the progression of renal disease: a meta analysis. Kidney Int ; 59:260-9.

.Frostegard J. (2005):-

SLE, atherosclerosis and cardiovascular disease. J Intern Med 257(6):485–495.

.Frostegard J, Svenungsson E,Wu R, et al. (2005):-

Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52(1):192–200.

. Furie R. (2006):-

Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus. *Rheum Dis Clin North Am.* ;32(1):149-56.

(G)

.Gabay C, Kushner I. (1999):-

Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 340(6):448–454.

. Garton M.J., and Isenberg D.A. (1997):-

Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. *Br. J. Rheumatol.*; 36: 1067.

.Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. (2002):-

The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas— a randomized trial. *Diabetes Res Clin Pract* 55:209–219.

. Gigante A., Amoroso D., et al., (2006):-

Systemic lupus erythematosus and renal involvement: which role of cytokines expression?. *Eur Rev Med Pharmacol Sci.*; 10 (5):223-8.

.Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT. (2005) :-

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med.* ;353(21):2219-28.

. Gladman D.D, Urowitz M.B and Goldsmith C.H. *et al.*, (1997):-

The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with

systemic lupus erythematosus, *Arthritis and Rheumatism* 40 (5), pp. 809–813.

. Gladman D.D., and Urowitz M.B., (1997): -

"Systemic lupus erythematosus, clinical and laboratory features". *Primer on the Rheumatic Diseases*, 11th edition. Klippel J.H. (editor), Chap. 19:215-257.

. Gladman D.D. and Urowitz M.B., (1999):-

The SLICC/ACR damage index progress report and experience in the field, *Lupus* (8), pp. 632–637.

.Goldberg IJ. (1996):-

Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis. *J Lipid Res* 37:693–707.

.Golbus J. McCune WJ.,(1994):-

Lupus nephritis: classification, prognosis, immunopathogenesis and treatment. *Rhem Dis Clinic North Am*;20:213-42.

. Gordon K.W, Michelle P. (2005):-

Assessment of systemic lupus erythematosus. *Clin Exp Rheumatol*; 23 (Suppl. 39) S120-S132.

.Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA (1989):-

"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies". *Circulation* 79 (1): 8–15.

.Gotto AM and Brinton EA (2004):-

Assesing low levels of high-density lipoprotein cholesterol as a risk factor in

coronary heart disease: a working group report and update. J Am Coll Cardiol; 43:717-724.

.Gourley MF, Austin HA 3rd, Scott D, et al. (1996):-

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. ;125(7):549-57

. Grande JP, (1998):-

Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus. ;7(9):604-10

.Grande JP and Balow JE, (1998):-

Renal biopsy in lupus nephritis. Lupus. ;7(9):611-7.

.Griffin BA, Freeman DJ, Tait GW, et al(1994):-

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis, 106:241–253.

.Grimaldi CM, Michael DJ, and Diamond B, (2001):-

Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J.Immunol. 167: 1886-1890.

(H)

.Hahn BH, Karpouza GA, Tsao BP, (2005):-

. Pathogenesis of systemic lupus erythematosus. In: Harris ED, et al. Eds. Kelley's Textbook of Rheumatology, 7th edition. ;1174-1200.

.Hahn BH, (2005):-

Management of Systemic Lupus Erythematosus. In: Harris ED, et al, eds. Kelley's Textbook of Rheumatology. 7th ed.:1225-47

. Haines TH (2001):-

"Do sterols reduce proton and sodium leaks through lipid bilayers?". Prog. Lipid Res. 40 (4): 299–324.

. Harley J.B., Sestak A.I, and Willis L.F. (1992):-

A model for disease heterogeneity in systemic lupus erythematosus. Arthritis Rheum. 32: 826

. Harley JB, Kelly JA, Kaufman KM, (2006) :-

Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol.; 28(2): 119-30.

.Hayata AL, Borba EF, Bonfa E et al ., (2005):-

The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile onset systemic lupus erythematosus. Lupus 14: 613-617.

.Heinecke JW. 1997:-

Mechanisms of oxidative damage of low-density lipoprotein in human atherosclerosis. Curr Opin Lipidol 8:268–274.

.Henkin Y, Como JA, Oberman A. 1992:-

Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 267:961–968.

.Hildebrand J, Muller D, Carlos J L, Talavera F and Herbert SD, (2005):-

Systemic lupus erythematosus. *Arthritis & rheum.*; 52 (1):201-211.

.Hirano, Tsutomu; Nohtomi, Kyoko; Koba, Shinji; Muroi, Ayako; Ito, Yasuki (2008):-

"A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". *The Journal of Lipid Research* 49: 1130.

.Hochberg MC,(1997):-

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum.* ;40(9):1725.

. Houssiau FA and Ginzler EM, (2008):-

Current treatment of lupus nephritis. *Lupus.* ;17(5):426-30.

.Hyka N, Dayer JM, Modoux C, et al. 2001.

Apolipoprotein A-I inhibits the production of interleukin-1_α and tumor necrosis factor-_α by blocking contact-mediated activation of monocytes by T lymphocytes. *Blood* 97:2381–2389.

(I)

.Ilowite NT, Samuel P, Ginzler E, et al. 1988:-

Dyslipoproteinemia in pediatric systemic lupus erythematosus. *Arthritis Rheum* 31:859–863.

.Inoue S, Egashira K, Ni W, et al. 2002:-

Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. *Circulation* 106:2700–2706.

(J)

. Jacob CO, Fronek Z. and Lewis GD. (1990):-

Heritable major histocompatibility complex class II associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA; 87: 1233.

.Javitt NB (1994):-

"Bile acid synthesis from cholesterol: regulatory and auxiliary pathways". FASEB J. 8 (15): 1308–11.

.Jennekens FG, Kater L(2002):-

The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford).;41(6):605-18.

.Jennekens FG, Kater L, (2002):-

The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford). ;41(6):619-30.

. Jensen RG, Hagerty MM, McMahon KE (1978):-

"Lipids of human milk and infant formulas: a review" . Am J Clin Nutr 31 (6): 990–1016.

. Jialal I, Devaraj S, Venugopal SK (2004):-

C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 44:6–11.

.Jozélio Freire de Carvalho, Eloísa Bonfá, Eduardo Ferreira Borba (2008):-

Systemic lupus erythematosus and "lupus dyslipoproteinemia"

Autoimmunity reviews; 7(3):246-50.

(K)

.Kaisho T, Takeda K, Tsujimura T et al., (2001):-

L kappa B kinase alpha is essential for mature B cell development and function. J Exp Med. 193: 417-426.

.Karamehic J, Subasic D, Gavrankapetanovic F et al., (2007):-

The incidence of antinuclear antibodies (ANA) detected by indirect immunofluorescence assay (IFA) method. Med Arh; 61 (1) 9-16.

.Karp I, Abrahamowicz M, Fortin PR, et al (2008):-

Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008, 59:169–175.

.Kirou KA, Salmon JE and Crow MK, (2006):-

Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum Dis Clin North Am. ;32(1):103-19, ix

.Kiss E, Fazekas B, Tarr T et al, (2004):-

Lipid profile in patients with systemic lupus erythematosus, with special focus on lipoprotein (a) in lupus nephritis. Orv Hetil; 145(5):217-22.

.Kobayashi K, Matsuura E, Liu Q, et al. 2001:-

A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42(5):697–709.

. Kwiterovich Jr, PO (2000):-

"The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". The American journal of cardiology 86 (12A): 5L–10L.

.Kurzrock R, Rohde MF, Quesada JR et al., (1986):-

Recombinant gamma interferon induces hypertriglyceridemia and inhibit post-heparin lipase activity in cancer patients. J Exp Med ; 164:1093-1101.

(L)

.Lahita RG, Rivkin E, Cavanagh I, et al. (1993):-

Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574.

.Leong KH, Koh ET,Feng PH, et al.,(1994):-

Lipid profile in patients with systemic lupus erythematosus. J Rheumatol;21:1264-7.

.Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (2007):-

"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths". Lancet 370 (9602): 1829–39..

. Lewis GF, Rader DJ (2005):-

"New insights into the regulation of HDL metabolism and reverse cholesterol transport". Circ. Res. 96 (12): 1221–32.

.Libby P. (2001):-

Managing the risk of atherosclerosis: the role of high-density lipoprotein, Am J Cardiol; 88: 3N-8N.

.Libby P. (2002):-

Inflammation in atherosclerosis. *Nature* 420(6917):868–874, 19–26 December.

.Li Xiao, Chen Xiao-nong, Ren Hong et al., (2006):-

Dyslipidemia in patients with lupus nephritis. *J of Chinese microcirculation*.03.

.Lockshin MD, Salmon JE, Roman MJ (2001):-

Atherosclerosis and lupus: a work in progress. *Arthritis Rheum*, 44:2215–2217.

.Lockshin MD and Kirkland M, (2007):-

Biology of sex distribution of systemic lupus erythematosus. *Arthritis Rheum.* ; 57 (4) : 608-611.

.Looney RJ, Anolik J, Sanz I., (2006):-

New therapies for systemic lupus erythematosus: cellular targets. *Rheum Dis Clin North Am.* ; 32 (1): 201-15, xi.

.Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, et al. 2006:-

Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: Implications in autoimmunemediated atherosclerosis. *Lupus* 15(2):80–86.

.Lopes-Virella MF, Virella G 2004:-

Atherosclerosis and autoimmunity. *Clin Immunol Immunopathol*, 73:155–167.

(M)

.MacGregor AJ, Dhillon VB, Binder A, et al. 1992:-

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. *Ann Rheum Dis* 51:152–155.

.Magid MS, Kaplan C and Sammaritano LR, (1998):-

Placental pathology in systemic lupus erythematosus: A prospective study. Am. J. Obstet. Gynecol.; 179: 226.

.Maksimowicz-McKinnon K, Magder LS, Petri M (2006):-

Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol vol 33 no 12; 2458-2463.

.Malloy MJ, Kane JP: A risk factor for atherosclerosis 2001:-

triglyceride-rich lipoproteins. Adv Intern Med, 47:111–136.

.Manger K, Manger B. Repp R, et al.,(2002):-

Definition of risk factors for death, end stage renal disease, and thromboembolic events in monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis ;61:1065-70.

. Manger, Seelen, Marc A; Trouw, L A; Daha, M R , (2003):-

Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Current Opinion in Nephrology and Hypertension: November 2003 - Volume 12 - Issue 6 - pp 619-624

.Manzi S, Meilahn EN, Rairie JE, et al.,(1997):-

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol ; 145:408-15.

.Manzi S, Selzer F, Sutton-Tyrrel K, et al. 1999:-

Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51–60.

.Marschall HU, Einarsson C (2007):-

"Gallstone disease". J. Intern. Med. 261 (6): 529–42.

. Masters, K. (2009):-

"Lupus And Lipstick: The Industry Responds". The Internet Journal of Dermatology 7 (1).

. McDonagh J.E, Khamashta MA, and Menon S, (1997):

A young woman with SLE: Diagnostic and therapeutic challenges. Lupus; 6: 633.

.Meisinger C, Baumert J, Khuseyinova N, et al 2005:-

Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112:651–657.

.Meola M., Barsotti G., Cupisti A., Buoncristiani E. and Giovannetti S. (1994) :-

Free-hand ultrasound-guided renal biopsy: report of 650 consecutive cases. Nephron 67, pp. 425–430.

.Meyers, C. Daniel; Carr, Molly C.; Park, Sang; Brunzell, John D. (2003):-

"Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia". Annals of Internal Medicine 139 (12): 996. PMID 14678919.

.M Mahmood Hussain, (2000):-

"Review Article: A proposed model for the assembly of chylomicrons"; Arteriosclerosis; Vol. 148; pages 1-15.

(N)

.Nath SK, Kilpatrick J, Harley JB, (2004):-

Genetics of human systemic lupus erythematosus: the emerging picture. *Curr Opin Immunol.* ;16(6):794-800.

.Navab M, Ananthramaiah GM, Reddy ST, et al 2004:-

The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. *J Lipid Res* 45:993–1007.

.Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G and Isenberg DA, (2006):-

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. *Ann Rheum Dis.* ;65(7):942-945.

.Nikpour M, Gladman DD, Ibanez D, Bruce IN, Burns RJ, Urowitz MB(2009):-

Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. *J Rheumatol* 2009, 36:288-294.

.Nilsson J, Hansson GK 2008:-

Autoimmunity in atherosclerosis: a protective response losing control? *J Intern Med* 2008 263:464–478.

.Nolsae RL, Kelly J A, Pociot F, Moser K L , Kristiansen OP, Mandrup-Poulsen T and Barley J B, (2005):-

Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia. *Genes and Immunity* 6, 699-706.

(O)

.Okazaki, Mitsuyo; Sasamoto, Keiko; Muramatsu, Toshio; Hosaki, Seijin (1997):-

"Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry 43 (10): 1885.

. Olson RE (1998):-

"Discovery of the lipoproteins, their role in fat transport and their significance as risk factors". J. Nutr. 128 (2 Suppl): 439S–443S

.Ostlund RE, Racette, SB, and Stenson WF (2003):-

"Inhibition of cholesterol absorption by phytosterol-replete wheat germ compared with phytosterol-depleted wheat germ". Am J Clin Nutr 77 (6): 1385–1589.

(P)

.Padilla MU, Balada E, Chacon P, et al.,(2009):-

Changes in lipid profile between flare and remission of patients with SLE:A prospective study. J Rheumatol ;36:1639-45.

. Pawlina, Wojciech; Ross, Michael W. (2006):-

Histology: a text and atlas: with correlated cell and molecular biology.
Philadelphia: Lippincott Williams & Wilkins. pp. 230.

.Pearson A, Budin M, Brocks JJ (2003):-

"Phylogenetic and biochemical evidence for sterol synthesis in the bacterium Gemmata obscuriglobus". Proc. Natl. Acad. Sci. U.S.A. 100 (26): 15352–7.

.Petri M, Perez-Gutthann S, Spence D, et al.,(1992):-

Risk factors for coronary artery disease in patients with systemic lupus erythematosus.Am J Med;93:513-9.

.Petri M, Lakata C, Magder L, Goldman D. 1994:-

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. *Am J Med* 96:254–259.

.Petri M, (1995):-

Clinical features of systemic lupus erythematosus (review). *Curr. Opin. Rheumatol.*; 7: 395.

.Petri M and Brodsky R, (2006):-

High-Dose Cyclophosphamide and Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus Michelle, *JAMA.*; 295:559-560.

.Pisetsky DS, Gilkeson G and Clair EW, (1997):-

Systemic lupus erythematosus. Diagnosis and treatment. *Med Clin North Am.* ;81(1):113-128.

(R)

.Rader, Daniel J. (2004):-

"Raising HDL in Clinical Practice". *Raising HDL in Clinical Practice: Clinical Strategies to Elevate HDL.*

.Rahman P, Gladman DD and Urowitz MB. (1998):-

Clinical predictors of fetal outcome in systemic lupus erythematosus. *J. Rheumatol.*; 25:126.

. Reefman P, Kuiper H, Limburg PC et al., (2007):-

Type I interferons are involved in the development of UVB induced inflammatory skin lesions in Systemic Lupus Erythematosus (SLE) patients. *Ann Rheum Dis*, 57:411.

.Reichlin M, Fesmire J, Quintero-Del-Rio AI, et al. (2002):-

Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. *Arthritis Rheum* 46(11): 2957–2963.

.Rhodes, Carl; Stryer, Lubert; Tasker, Roy (1995):-

Biochemistry (4th ed.). San Francisco: W.H. Freeman. pp. 280, 703.

. Richter CM, Steiner G, Smolen JS and Isenberg DA (1998):-

Erosive arthritis in systemic lupus erythematosus: Analysis of a distinct clinical and serological subset. *Br. J. Rheumatol.*; 37:421.

.Riess MD 2009:-

Effect of inflammation on cholesterol metabolism and its impact on patients with systemic lupus erythematosus.

. Ringold, (2006):-

Systemic Lupus Erythematosus *JAMA Journal*. Vol (293) No (23).

.Rollino C., Garofalo G., Roccatello D., Sorrentino T., et al., (1994) :-

Colour-coded Doppler sonography in monitoring native kidney biopsies. *Nephrol. Dial. Transplant* 9, pp. 1260–1263.

.Roman MJ, Shanker BA, Davis A et al.,(2003):-

Prevalance and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med*;349:2399-406.

s.Rönnblom L and Pascual V, (2008):-

The innate immune system in SLE: type I interferons and dendritic cells. *Lupus*. ;17(5):394-9.

.Ross R. 1999:-

Atherosclerosis—an inflammatory disease. *N Engl J Med* 340(2):115–126.

.Rothfield NF, (1993):-

SLE: clinical aspects and treatment. *Arthritis and Allied conditions. A Text book of Rheumatology* 12thed. 155-1177.

.Rus V, Maury EE and Hochberg MC, (2007):-

Epidemiology of Systemic Lupus Erythematosus. In: Wallace DJ, Hahn BH, eds. *Dubois' Lupus Erythematosus*. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; :34-44.

(S)

.Salmon JE and Kimberly RP (2006):-

Systemic lupus erythematosus In *Manual of rheumatology and outpatient orthopedic disorders*; Fifth edition 221-237.

.Sarkissian T, Beyenne J, Beldman B et al., (2006):-

The complex nature of interaction between disease activity and therapy on lipid profile in patients with pediatric systemic lupus erythematosus. *Arthritis Rheum*;54: 1283-1290.

. Scaballer JG, (1997):-

Systemic lupus erythematosus. In: *Nelson Textbook of paediatrics*. Behraman R.B., Kliegman R.M. and Arvin A.M.(eds). 15th edition. W.B. Saunders Company. Philadelphia, London, Toronto, Montreal, Sydney,

Tokyo.Pp:673.

.Schaefer EJ, et al. 1987:-

Plasma triglycerides in regulation of HDL cholesterol levels. *Lancet* ii:391–392.

.Segrest JP, Jones MK, De Loof H, Dashti N (September 2001):-

"Structure of apolipoprotein B-100 in low density lipoproteins". *Journal of Lipid Research* 42 (9): 1346–67. PMID 11518754.

.Sella EM, Sato EI and Barbieri A (2003):-

Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. *Arthritis Rheum*;22: 357.

.Selzer F, Sutton-Tyrrell K, Fitzgerald SG et al., (2004):-

Comparison of risk factors for vascular disease in carotid artery and aorta in women with systemic lupus erythematosus. *Arthritis Rheum*; 50(1): 151-159.

.Serikova Slu, Kozlovskaja NL, Shilov EM, (2008):-

Lupus nephritis as a factor of atherosclerosis risk in patients with systemic lupus erythematosus. *Ter Arkh*;80(6): 52-8.

.Sharrett AR, Ballantyne CM, Coady SA, et al (2001):-

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation*, 104:1108–1113.

.Shearer GC, Stevenson FT, Atkinson DN et al., (2001):-

Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in nephrotic syndrome. *Kidney Int* ; 59P179-189.

.Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995):-

"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group". N. Engl. J. Med. 333 (20): 1301–7.

.Shoenfeld Y, Gerli R, Doria A, et al. 2005:-

Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347.

.Sholter DE, Armstrong PW. 2000:-

Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 16:505–511.

.Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C and Arrigo G, (2006):-

Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci. ;1050:193-200.

.Siripaitoon B, Osin M, Vongthavarvat V et al., (2004):-

The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. Lupus;961-968.

.Somers EC, Marder W, Christman GM, Oggenovski V and McCune WJ, (2005):-

Use of a gonadotropin-releasing hormone analogue for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. ;52(9):2761-7.

.Sontheimer RD, (1996):-

Photo-immunology of lupus erythematosus and dermatomyositis: A speculative review. Photochem. Photobiol.; 63: 583.

.Soudijn W, van Wijngaarden I, Ijzerman AP (2007):-

"Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews 27 (3): 417–33.

.Spronk PE, Ter Borg EJ, Limburg PC, et al. 1992:-

Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol 90:106–110.

.Stoll T, Sutcliffe N, Mach J. et al., (2004):-

Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study, Rheumatology (Oxford) 43 (2004) (8), pp. 1039–1044.

.Studnicka-Benke A, Steiner G, Petera P, Smolen JS1996:-

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol, 35:1067–1074.

. Superko HR, Nejedly M, Garrett B (2002):-

"Small LDL and its clinical importance as a new CAD risk factor: a female case study". Progress in Cardiovascular Nursing 17 (4): 167–73.

.Svenungsson E, Jensen-Urstd K, Heimbürger M, et al.,(2001):-

Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation;104: 1887 -1893.

.Svenungsson E, Gunnarsson I, Fei G et al (2003):-

Elevated triglycerides and low level of high density lipoproteins as markers of disease activity in association with upregulation of TNF α TNF receptor system in SLE patients. Arthritis & Rheum;48:2533-2540.

.Szekanecz Z, Shoenfeld Y 2006:-

Lupus and cardiovascular disease: the facts. *Lupus* 2006, 15(Suppl 11):3–10.

(T)

.Tam LS, Gladman DD, Hallett DC et al., (2000):-

Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. *J Rheumatol*;27:2142-5.

.Tisseverasinghe A, Lim S, Greenwood C et al., (2006):-

Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. *Arthritis Rheum*;54:2211-2219.

.Trager J, Ward MM (2001):

Mortality and causes of death in systemic lupus erythematosus. *Curr Opin Rheumatol.* ;13(5):345-51.

.Tsao BP, (2004):-

Update on human systemic lupus erythematosus genetics. *Curr Opin Rheumatol.* ;16(5):513-21.

.Tymoczko, John L, Stryer Berg Tymoczko; Stryer, Lubert; Berg, Jeremy Mark (2002):-

Biochemistry. San Francisco: W.H. Freeman. pp. 726–727. ISBN 0-7167-4955-6.

(U)

.Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA,(1976):-

The bimodal mortality pattern of systemic lupus erythematosus. Am J Med.
;60(2):221-5.

.Urowitz MB, Ibanez D, Gladman DD (2007):-

Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol, 34:70-75.

(V)

.Vaarala O, Alfthan G, Jauhiainen M, et al. 1993:-

Crossreaction between antibodies to oxidised low density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341: 923–925.

.Van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ (2008):-

"High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies". J. Am. Coll. Cardiol. 51 (6): 634–42.

.Vazquez-Perez S, Aragoncillo P, de Las HN et al., (2001):-

Atrovastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolemic rabbits. Nephrol Dial Transplant; 16 Suppl 1:40-4.

.Vergnani L, Hatrik S, Ricci F, et al 2000:-

Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. *Circulation*, 101:1261–1266.

(W)

. Wajed J, Ahmad Y, Durrington PN, Bruce IN,(2004):-

Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. *Rheumatology (Oxford)*. 43(1):7-12.

.Wallace DJ, Metzger AL, Stecher VJ, Tumbull BA, Kern PA. 1990:-

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. *Am J Med* 89:322–326.

.Wallace DJ and Metzger AL. (1997):-

Systemic Lupus Erythematosus: Clinical aspects and treatment. In: *Arthritis and allied conditions: A ' textbook of rheumatology*. Edited by: William J. Koopman, and Daniel J. McCarty. 13th edition. Chap. 69; P. 1319.

.Walz Le Blanc BA, Dagenais P and Urowitz MB, (1994):-

Methotrexate in systemic lupus erythematosus. *J. Rheumatol.*;21: 836.

.Wang B, Gladman DD and Urowitz MB. (1998):-

Fatigue in lupus is not correlated with disease activity.. *J. Rheumatol.*;25: 892.

. Wang J, Kay AB, Fletcher J, Formica MK & McAlindon TE (2008):-

"Is lipstick associated with the development of systemic lupus erythematosus

(SLE)?". Clinical Rheumatology 29 (9): 1183–1197.

.Warnick GR, Knopp RH, Fitzpatrick V, Branson L (1990):-

"Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints". Clin. Chem. 36 (1): 15–9.

.Wasko MC (2004):-

Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol, 16:109–113.

.Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE and Appel GB, (2004):-

The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. ;15(2):241-50.

.Werth VP, Duti JP, and Southerner RD, (1997):

Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus (review). Curr. Opin. Rheumatol.; 9: 400.

.Whittier WL and Korbet SM (2004):-

Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol.;15(1):142-7.

.Winslow TM, Ossipov MO, Fazio GP and Simonson JS (1995):-

Five- year follow- up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am. Heart J.; 129: 510- 515.

. Wiseman D.A., Hawkins R., Numerow L.M. and Taub K.J. (1990) :-

Percutaneous renal biopsy utilizing real time, ultrasonic guidance and a

semiautomated biopsy device. *Kidney Int.* **38**, pp. 347–349.

.Wolkoff AW, Cohen DE (2003):-

"Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids".
Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2): G175–9.

.Wong M and Tsao BP, (2006):-

Current topics in human SLE genetics. Springer Semin
Immunopathol. ;28(2):97-107.

(Y)

.Yung S and Chan TM, (2008):-

Anti-DNA antibodies in the pathogenesis of lupus nephritis--the emerging
mechanisms. *Autoimmun Rev.* ;7(4):317-21